Imiquimod 5 percent cream and the treatment of cutaneous malignancy

Dermatology Online Journal

Volumn 10, Issue 1, 2004, Pages

  Navi, Daniel ^a   Huntley, Arthur ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; BLEEDING; BOWEN DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDEMA; EROSION; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; KERATOACANTHOMA; MALIGNANT LENTIGO; MELANOMA; MYCOSIS FUNGOIDES; PAGET SKIN DISEASE; PAIN; PRURITUS; RASH; REVIEW; SIDE EFFECT; SKIN CANCER; SKIN MANIFESTATION; SKIN METASTASIS; SQUAMOUS CELL CARCINOMA; APOPTOSIS; CELLULAR IMMUNITY; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG SCREENING; FEMALE; KERATOSIS; MALE; METASTASIS; MULTICENTER STUDY; OINTMENT; PRECANCER; RANDOMIZED CONTROLLED TRIAL; SKIN TUMOR; TUMOR CELL LINE;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BOWEN'S DISEASE; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CLINICAL TRIALS; CONDYLOMATA ACUMINATA; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; KERATOACANTHOMA; KERATOSIS; MALE; MELANOMA; MULTICENTER STUDIES; MYCOSIS FUNGOIDES; OINTMENTS; PAGET'S DISEASE, EXTRAMAMMARY; PRECANCEROUS CONDITIONS; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS;

EID: 6044260163     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Stanley, MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol. 2002 Oct;27(7):571-7.
2. Garland, SM. Imiquimod. Curr Opin Infect Dis. 2003 Apr;16(2):85-9.
3. Skinner, RB Jr. Dermatol Clin. 2003 Apr;21(2):291-300.
4. Berman B, Sullivan T, De Araujo T, and M. Nadji. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol. 2003 Nov;149 Suppl 66:59-61.
5. Schon M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, Benninghoff B, Slade HB, Gollnick H, and MP Schon. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst. 2003 Aug 6;95(15):1138-49.
6. Walker, JK and C. Koenig. Is imiquimod effective and safe for actinic keratosis? J Fam Pract. 2003 Mar;52(3):184-5.
7. Stockfleth E, Meyer T, Beninghoff B, and E. Christophers. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol. 2001 May;144(5):1050-3.
8. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. J Am Acad Dermatol. 2002 Oct;47(4):571-7.
9. Beutner KR, Geisse JK, Helman D, Fox TL, Geinkel A, and ML. Owens. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999 Dec;41(6):1002-7.
10. Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL, and ML. Owens. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 2001 May;44(5):807-13.
11. Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, and ML. Owens. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002 Sep;47(3):390-8.
12. Sterry W, Rtzicka T, Herrera E, Takwale A, Bichel J, Andres K, Ding L, and MR Thissen. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 2002 Dec;147(6):1227-36.
13. Shumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter A, Andres K, Amies M, Owens M. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol. 2002 Sep;138(9):1165-71.
14. Eklind J, Maschke J, Lindbrink P, Hengge UR, and U. Tartler. Imiquimod to treat different cancers of the epidermis. Dermatol Surg. 2003 Aug;29(8):890-6; discussion 896.
15. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, and ML. Owens. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol. 2001 Mar;44(3):462-70.
16. Wu JK, Siller G, Whitehead K. Treatment of Bowen's disease and basal cell carcinoma of the nose with imiquimod 5% cream. Australas J Dermatol. 2003 May;44(2):123-5.
17. Schroeder TL, and RD. Sengelmann. Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol. 2002 Apr;46(4):545-8.
18. Ahmed I, and J. Berth-Jones. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol. 2000 Oct;143(4):843-5.
19. Chapman MS, Spencer SK, and JB. Brennick. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol. 2003 Jul;139(7):943-4.
20. Naylor MF, Crowson N, Kuwahara R, Teague K, Garcia C, Mackinnis C, Haque R, Odom C, Jankey C, Cornelison RL. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003 Nov;149 Suppl 66:66-70.
21. Steinmann A, Funk JO, Schuler G, and P. von den Driesch. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol. 2000 Sep;43 (3):555-6.
22. Wolf IH, Smolle J, Binder B, Cerroni L, Richtig E, Kerl H. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol. 2003 Mar;139 (3):273-6.
23. Ugurel S, Wagner A, Pfohler C, Tilgen W, and U. Reinhold. Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. Br J Dermatol. 2002 Sep;147(3):621-4.
24. Drummer R, Urosevic M, Kempf W, Kzakov D, and G. Burg. Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology. 2003;207(1):116-8.
25. Dendorfer M, Oppel T, Wollenberg A, and JC. Prinz. TTopical treatment with imiquimod may induce regression of facial keratoacanthoma. Eur J Dermatol. 2003 Jan-Feb;13(1):80-2.
26. Zamponga JC, Flowers FP, Roth WI, and AM. Hassenein. Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports. J Am Acad Dermatol. 2002 Oct;47(4 Suppl):S229-35.
27. Qian Z, Zeitoun NC, Shieh S, Helm T, and AR. Oseroff. Successful treatment of extramammary Paget's disease with imiquimod. J Drugs Dermatol. 2003 Jan;2 (1):73-6.